Eton Pharmaceuticals, Inc.
$46.42-5.3%YTD+190.5%1Y+227.8%
Mentions · last 7 days
89
Price updated 5h ago·X counts updated 3h ago
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $ETON.
Drug Manufacturers - Specialty & Generic
No material change from last week — animal health revenues under pressure from inflation-driven vet visit deferrals while a securities fraud investigation adds governance overhang; the key debate..
Top industry ETF
$IHEiShares U.S. Pharmaceuticals ETF
+20.5%YTD
+54.6%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-959.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
3.1%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
2.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
1.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
15.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-5.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
54.8%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q1 2026May 14, 2026$0.05$0.10-50.0%
Q4 2025Mar 19, 2026$0.05$0.12-58.3%
Q3 2025Nov 6, 2025$-0.07$0.16-143.8%
Q2 2025Aug 7, 2025$-0.10$-0.01-900.0%
Next earningsThu, Aug 6·consensus EPS $0.13
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$24.3M+40.4%60.7%9.9%$0.06$7.3M
Q4 FY25$21.3M+82.7%61.6%11.6%$0.06$-11.6M
Q3 FY25$22.5M+117.5%35.0%-6.1%$-0.07$11.7M
Q2 FY25$18.9M+108.6%63.0%-7.8%$-0.10$8.0M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$115.5M$115.4M – $115.5M$0.86$0.78 – $0.943
FY27$186.9M$180.7M – $193.1M$2.04$1.96 – $2.123
FY28$251.5M$236.7M – $275.4M$3.16$2.58 – $3.684
FY29$340.1M$327.9M – $351.8M$4.75$4.53 – $4.963
FY30$426.0M$410.6M – $440.6M$6.28$5.99 – $6.563
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.97%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+37.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+108.6%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 21.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.865-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KShareholder voteJun 98-K — Item 5.07: Shareholder vote
AI summary
3New insider — initial holdingsJun 13
AI summary
8-KMaterial agreementMay 198-K — Item 1.01: Material agreement · Item 2.01: Acquisition completed
8-KOfficer or director changeApr 168-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
8-KMaterial agreementApr 158-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
8-KMaterial agreementMar 28-K — Item 1.01: Material agreement · Item 2.01: Acquisition completed
+ 13 other (5 routine 8-Ks · 2 13Gs · 2 earnings 8-Ks · 1 10-Q) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Eton Pharmaceuticals Announces Submission of Prior Approval Supplement to Expand Indication of KHINDIVI® (hydrocortisone) Oral SolutionEton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?Eton Pharmaceuticals Inc (ETON) Shares Fall 4.3% -- What GF Score of 70 Tells InvestorsEton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript
More in Drug Manufacturers - Specialty & Generic
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · top 2 · last 7 days